[{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"PROTACs","year":"2021","type":"Inapplicable","leadProduct":"Luxdegalutamide","moa":"Androgen receptor||Androgen receptor (AR)","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"PROTACs","year":"2025","type":"Inapplicable","leadProduct":"Luxdegalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"PROTACs","year":"2025","type":"Inapplicable","leadProduct":"Luxdegalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"Luxdegalutamide","moa":"NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Licensing Agreement","leadProduct":"Luxdegalutamide","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":1.1599999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.1599999999999999,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Novartis Pharmaceuticals Corporation"}]

Find Clinical Drug Pipeline Developments & Deals for Luxdegalutamide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : JSB462 (Luxdegalutamide) is a PROTACs drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                          Product Name : JSB462

                          Product Type : PROTACs

                          Upfront Cash : Inapplicable

                          July 02, 2025

                          Lead Product(s) : Luxdegalutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : JSB462 (Luxdegalutamide) is a PROTACs drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : JSB462

                          Product Type : PROTACs

                          Upfront Cash : Inapplicable

                          May 28, 2025

                          Lead Product(s) : Luxdegalutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Novartis obtains worldwide development & commercialization rights to ARV-766, Arvinas’ 2nd-generation PROTAC androgen receptor degrader for prostate cancer, including its preclinical AR-V7 program.

                          Product Name : Undisclosed

                          Product Type : PROTACs

                          Upfront Cash : $150.0 million

                          April 11, 2024

                          Lead Product(s) : Luxdegalutamide,Abiraterone Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : $1,160.0 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to degrade all clinically relevant resistance-driving point mutations of the androgen receptor (AR) and which being investigated forLate-line mCRPC.

                          Product Name : Undisclosed

                          Product Type : PROTACs

                          Upfront Cash : Inapplicable

                          June 08, 2023

                          Lead Product(s) : Luxdegalutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : ARV-766 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : PROTACs

                          Upfront Cash : Inapplicable

                          October 05, 2021

                          Lead Product(s) : Luxdegalutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank